<DOC>
	<DOC>NCT00501969</DOC>
	<brief_summary>The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease</brief_summary>
	<brief_title>An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease</brief_title>
	<detailed_description>This is the open-label extension to the randomized, double-blind, placebo-and active controlled SP515 (NCT00244387) trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease that were not well-controlled on levodopa</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects who have completed four months of maintenance treatment in the SP515 (NCT00244387) doubleblind trial Subjects who had an ongoing serious adverse event from SP515 (NCT00244387) doubleblind trial that was assessed as related to study medication</criteria>
	<gender>All</gender>
	<minimum_age>31 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>NeuproÂ®</keyword>
</DOC>